Guerbet announced Friday evening the appointment of Hugues Lecat as Chairman of the Board of Directors, in line with the timetable previously announced by the specialist in contrast products and solutions for medical imaging.

This appointment at the close of the AGM brings to an end, with immediate effect, the duties of censor which he had held since March 20. Didier Izabel remains a director and Chairman of the Audit Committee until his term of office expires in 2026.

Hugues Lecat was CEO and then Chairman of the Supervisory Board of Ethypharm, which he transformed into an international pharmaceutical group focused on the central nervous system and injectable products for hospitals.

Copyright (c) 2024 CercleFinance.com. All rights reserved.